Study drug levels in people with mild or moderate liver problems
This Phase 1 study measures how tasurgratinib (E7090) and its breakdown product move through the body in people with mild or moderate liver impairment. It aims to understand appropriate dosing and safety considerations for liver impairment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your BMI is between 18 and 40.
- If you have liver problems, they must be stable and fall in Child-Pugh class A or B (mild to moderate).
- If you are healthy, you must be matched to a liver-impaired participant by age, body weight, race, and gender.
- Your ECG must not show a dangerously long QTc (QTcF must be 480 milliseconds or less).
- You must not have certain serious current eye problems (like corneal disease or active macular disorders).
- For people with liver problems: no major new illness in the last 8 weeks, and your related medicines must be stable for at least 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This trial tests how the body processes quizartinib when the liver is severely impaired. It helps doctors understand if the dose needs to be adjusted for patients with liver issues.
This Phase 1 trial studies how saroglitazar magnesium works in people with liver scarring (cirrhosis) caused by a bile-flow problem. It helps doctors understand safety and how the body handles the medicine in this specific liver condition.
This study tests an experimental drug called tacabrutideg in people with moderate or severe liver damage, as well as in people with normal liver function. The goal is to see how the drug is processed by the body and whether it is safe to take when your liver is not working normally.
This study tests how an experimental drug (TS-172) is processed in the body by comparing people with mild to moderate liver disease to those with normal liver function. It may help doctors understand how to dose the drug safely for people with liver problems.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.